Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 8/20 | 0.67 |
| ▸ | DRD2 | P14416 | 7/20 | 0.63 |
| ▸ | DRD3 | P35462 | 5/20 | 0.63 |
| ▸ | HTR1A | P08908 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6585625 | 0.97 | DRD4 (0.63) | DRD4DRD2DRD3HTR1AHTT | |
| SCHEMBL29188191 | 0.96 | DRD4 (0.67) | DRD4DRD2DRD3HTR1AHTT | |
| SCHEMBL2395803 | 0.90 | LMNA (0.60) | DRD4DRD2DRD3HTR1AHTT | |
| SCHEMBL10287534 | 0.90 | SIGMAR1 (0.71) | DRD4DRD2DRD3HTR1AHTT | |
| SCHEMBL12499169 | 0.89 | DRD4 (0.56) | DRD4DRD2DRD3HTR1AHTT | |
| SCHEMBL7975118 | 0.89 | DRD4 (0.59) | DRD4DRD2DRD3HTR1AHTT | |
| SCHEMBL2392338 | 0.89 | DRD4 (0.56) | DRD4DRD2DRD3HTR1AHTT | |
| SCHEMBL2582694 | 0.89 | HDAC4 (0.58) | DRD4DRD2DRD3HTR1AHTT | |
| SCHEMBL2395917 | 0.89 | MAPK1 (0.69) | DRD4DRD2DRD3HTR1AHTT | |
| SCHEMBL13959654 | 0.89 | DRD4 (0.56) | DRD4DRD2DRD3HTR1AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116803980-A | Preparation method of tetrahydropyridine derivative and hexahydropyridine derivative | 中国科学院化学研究所 | 2023-09-26 | — | — | CN | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-3773576-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| CN-111902141-A | Glucocerebroside binders for IKAROS degradation | C4医药公司 | 2020-11-06 | — | — | CN | disclosed |
| WO-2019191112-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-19 | — | — | US | disclosed |
| EP-0937715-A1 | TETRAHYDROBENZINDOLE COMPOUNDS | MEIJI SEIKA KAISHA LTD. (JP) | 1999-08-25 | — | — | EP | disclosed |
| US-5912350-A | Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands | NEUROGEN CORPORATION (US) | 1999-06-15 | — | — | US | disclosed |
| US-5880284-A | HAVING ANTITHROMBOTIC, ANTIAGGREGATORY AND TUMOR- OR METASTASES-INHIBITING EFFECTS | DR. KARL THOMAE GMBH (DE) | 1999-03-09 | — | — | US | disclosed |
| US-5681841-A | PREVENTION CELL AGGREGATION | KARL THOMAE GMBH (DE) | 1997-10-28 | — | — | US | disclosed |
| US-5677454-A | DIAGNOSIS, THERAPY OF SCHIZOPHRENIA, DEPRESSION, PARKINSONISM | NEUROGEN CORPORATION (US) | 1997-10-14 | — | — | US | disclosed |
| EP-0587134-A2 | Cyclic urea derivatives, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1994-03-16 | — | — | EP | disclosed |
| EP-0059989-A1 | 2,3- and 3,4-dehydro-5-phenylmorphans and their preparation | ELI LILLY AND COMPANY (US) | 1982-09-15 | — | — | EP | disclosed |
| US-4278797-A | Intermediates to phenylmorphans and method of preparation thereof | ELI LILLY AND COMPANY (US) | 1981-07-14 | — | — | US | disclosed |
| EP-0018077-A2 | Phenylmorphans, processes for their preparation and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1980-10-29 | — | — | EP | disclosed |
| US-4132710-A | DIURETICS, ANOREXICS, ANTIDEPRESSANTS, ANTICONVULSANTS, & ANTIHYPERTENSIVE AGENTS | AYERST, MCKENNA AND HARRISON, LTD. (CA) | 1979-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | TRPV1, TRPA1, KCNJ2 | DRD4 2256/4885DRD2 1111/4885DRD3 1770/4885 |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | DRD4 4618/4885DRD2 4728/4885DRD3 4466/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | DRD4 3890/4885DRD2 4247/4885DRD3 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.